{"doc_id": "33115675", "type of study": "Therapy", "title": "", "abstract": "Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial.\nEffective antiviral drugs for COVID-19 are still lacking.\nThis study aims to evaluate the clinical outcomes and plasma concentrations of baloxavir acid and favipiravir in COVID-19 patients.\nFavipiravir and baloxavir acid were evaluated for their antiviral activity against SARS-CoV-2 in vitro before the trial initiation.\nWe conducted an exploratory trial with 3 arms involving hospitalized adult patients with COVID-19.\nPatients were randomized assigned in a 1:1:1 ratio into baloxavir marboxil group, favipiravir group, and control group.\nThe primary outcome was the percentage of subjects with viral negative by Day 14 and the time from randomization to clinical improvement.\nVirus load reduction, blood drug concentration and clinical presentation were also observed.\nThe trial was registered with Chinese Clinical Trial Registry (ChiCTR 2000029544).\nBaloxavir acid showed antiviral activity in vitro with the half-maximal effective concentration (EC50) of 5.48 \u03bcM comparable to arbidol and lopinavir, but favipiravir didn't demonstrate significant antiviral activity up to 100 \u03bcM. Thirty patients were enrolled.\nThe percentage of patients who turned viral negative after 14-day treatment was 70%, 77%, and 100% in the baloxavir marboxil, favipiravir, and control group respectively, with the medians of time from randomization to clinical improvement was 14, 14 and 15 days, respectively.\nOne reason for the lack of virological effect and clinical benefits may be due to insufficient concentrations of these drugs relative to their antiviral activities.\nOne of the limitations of this study is the time from symptom onset to randomization, especially in the baloxavir marboxil and control groups, which is higher than the favipiravir group.\nOur findings could not prove a benefit of addition of either baloxavir marboxil or favipiravir under the trial dosages to the existing standard treatment.\nCopyright \u00a9 2020.\nPublished by Elsevier B.V.\n", "Evidence Map": {"Enrollment": [{"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 85, "end": 93}, {"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 113, "end": 121}, {"term": "hospitalized adult patients", "negation": "affirmed", "UMLS": {}, "start": 56, "end": 83}, {"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 89, "end": 97}], "Comparison Results": [], "Study Arm 1 Results": [], "Study Arm 2 Results": [], "Hypothesis": []}, "Sentence-level breakdown": [{"Section": "TITLE", "Text": "Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients : An Exploratory Randomized , Controlled Trial .", "Evidence Elements": {"Participant": [{"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 85, "end": 93}], "Intervention": [{"term": "Baloxavir Marboxil", "negation": "affirmed", "UMLS": {}, "start": 47, "end": 65, "has_chemical": [{"text": "baloxavir marboxil", "maps_to": "C4688747:baloxavir marboxil", "start": 0, "end": 18}], "has_relation": "N/A"}, {"term": "Favipiravir", "negation": "affirmed", "UMLS": {}, "start": 70, "end": 81, "has_chemical": [{"text": "favipiravir", "maps_to": "C1138226:favipiravir", "start": 0, "end": 11}], "has_relation": "N/A"}], "Outcome": [{"term": "Plasma Concentrations", "negation": "affirmed", "UMLS": {}, "start": 22, "end": 43}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "BACKGROUND", "Text": "Effective antiviral drugs for COVID-19 are still lacking .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "BACKGROUND", "Text": "This study aims to evaluate the clinical outcomes and plasma concentrations of baloxavir acid and favipiravir in COVID-19 patients .", "Evidence Elements": {"Participant": [{"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 113, "end": 121}], "Intervention": [{"term": "baloxavir acid", "negation": "affirmed", "UMLS": {}, "start": 79, "end": 93, "has_chemical": [{"text": "baloxavir acid", "maps_to": "C0001128:acid", "start": 0, "end": 14}], "has_relation": "N/A"}, {"term": "favipiravir", "negation": "affirmed", "UMLS": {}, "start": 98, "end": 109, "has_chemical": [{"text": "favipiravir", "maps_to": "C1138226:favipiravir", "start": 0, "end": 11}], "has_relation": "N/A"}], "Outcome": [{"term": "clinical outcomes", "negation": "affirmed", "UMLS": {}, "start": 32, "end": 49}, {"term": "plasma concentrations", "negation": "affirmed", "UMLS": {}, "start": 54, "end": 75}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "Favipiravir and baloxavir acid were evaluated for their antiviral activity against SARS-CoV-2 in vitro before the trial initiation .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "Favipiravir", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 11, "has_chemical": [{"text": "favipiravir", "maps_to": "C1138226:favipiravir", "start": 0, "end": 11}], "has_relation": "N/A"}, {"term": "baloxavir acid", "negation": "affirmed", "UMLS": {}, "start": 16, "end": 30, "has_chemical": [{"text": "baloxavir acid", "maps_to": "C0001128:acid", "start": 0, "end": 14}], "has_relation": "N/A"}], "Outcome": [{"term": "antiviral activity against SARS-CoV-2", "negation": "affirmed", "UMLS": {}, "start": 56, "end": 93}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "We conducted an exploratory trial with 3 arms involving hospitalized adult patients with COVID-19 .", "Evidence Elements": {"Participant": [{"term": "hospitalized adult patients", "negation": "affirmed", "UMLS": {}, "start": 56, "end": 83}, {"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 89, "end": 97}], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "Patients were randomized assigned in a 1:1:1 ratio into baloxavir marboxil group , favipiravir group , and control group .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "baloxavir marboxil", "negation": "affirmed", "UMLS": {}, "start": 56, "end": 74, "has_chemical": [{"text": "baloxavir marboxil", "maps_to": "C4688747:baloxavir marboxil", "start": 0, "end": 18}], "has_relation": "N/A"}, {"term": "favipiravir", "negation": "affirmed", "UMLS": {}, "start": 83, "end": 94, "has_chemical": [{"text": "favipiravir", "maps_to": "C1138226:favipiravir", "start": 0, "end": 11}], "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "The primary outcome was the percentage of subjects with viral negative by Day 14 and the time from randomization to clinical improvement .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "percentage of subjects with viral negative by Day 14", "negation": "affirmed", "UMLS": {}, "start": 28, "end": 80}, {"term": "time from randomization to clinical improvement", "negation": "affirmed", "UMLS": {}, "start": 89, "end": 136}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "Virus load reduction , blood drug concentration and clinical presentation were also observed .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "Virus load reduction", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 20}, {"term": "blood drug concentration", "negation": "affirmed", "UMLS": {}, "start": 23, "end": 47}, {"term": "clinical presentation", "negation": "affirmed", "UMLS": {}, "start": 52, "end": 73}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "The trial was registered with Chinese Clinical Trial Registry ( ChiCTR 2000029544 ) .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "Baloxavir acid showed antiviral activity in vitro with the half-maximal effective concentration ( EC50 ) of 5.48 \u03bcM comparable to arbidol and lopinavir , but favipiravir didn 't demonstrate significant antiviral activity up to 100 \u03bcM . Thirty patients were enrolled .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "Baloxavir acid", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 14, "has_chemical": [{"text": "baloxavir acid", "maps_to": "C0001128:acid", "start": 0, "end": 14}], "has_relation": "N/A"}, {"term": "arbidol", "negation": "affirmed", "UMLS": {}, "start": 130, "end": 137, "has_chemical": [{"text": "arbidol", "maps_to": "C5399815:arbidol", "start": 0, "end": 7}], "has_relation": "N/A"}, {"term": "lopinavir", "negation": "affirmed", "UMLS": {}, "start": 142, "end": 151, "has_chemical": [{"text": "lopinavir", "maps_to": "C0674432:lopinavir", "start": 0, "end": 9}], "has_relation": "N/A"}, {"term": "favipiravir", "negation": "affirmed", "UMLS": {}, "start": 158, "end": 169, "has_chemical": [{"text": "favipiravir", "maps_to": "C1138226:favipiravir", "start": 0, "end": 11}], "has_relation": "N/A"}], "Outcome": [{"term": "antiviral activity", "negation": "affirmed", "UMLS": {}, "start": 22, "end": 40}, {"term": "half-maximal effective concentration ( EC50 )", "negation": "affirmed", "UMLS": {}, "start": 59, "end": 104}, {"term": "antiviral activity", "negation": "affirmed", "UMLS": {}, "start": 22, "end": 40}], "Observation": [{"term": "5.48 \u03bcM", "negation": "affirmed", "UMLS": {}, "start": 108, "end": 115}, {"term": "comparable", "negation": "affirmed", "UMLS": {}, "start": 116, "end": 126}, {"term": "significant", "negation": "affirmed", "UMLS": {}, "start": 190, "end": 201}], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "The percentage of patients who turned viral negative after 14-day treatment was 70 % , 77 % , and 100 % in the baloxavir marboxil , favipiravir , and control group respectively , with the medians of time from randomization to clinical improvement was 14 , 14 and 15 days , respectively .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "baloxavir marboxil", "negation": "affirmed", "UMLS": {}, "start": 111, "end": 129, "has_chemical": [{"text": "baloxavir marboxil", "maps_to": "C4688747:baloxavir marboxil", "start": 0, "end": 18}], "has_relation": "N/A"}, {"term": "favipiravir", "negation": "affirmed", "UMLS": {}, "start": 132, "end": 143, "has_chemical": [{"text": "favipiravir", "maps_to": "C1138226:favipiravir", "start": 0, "end": 11}], "has_relation": "N/A"}, {"term": "control", "negation": "affirmed", "UMLS": {}, "start": 150, "end": 157, "has_relation": "N/A"}], "Outcome": [{"term": "percentage of patients who turned viral negative after 14-day treatment", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 75}, {"term": "medians of time from randomization to clinical", "negation": "affirmed", "UMLS": {}, "start": 188, "end": 234}], "Observation": [{"term": "70 %", "negation": "affirmed", "UMLS": {}, "start": 80, "end": 84}, {"term": "77 %", "negation": "affirmed", "UMLS": {}, "start": 87, "end": 91}, {"term": "100 %", "negation": "affirmed", "UMLS": {}, "start": 98, "end": 103}], "Count": []}, "Evidence Propositions": [{"Intervention": {"term": "favipiravir", "has_chemical": [{"text": "favipiravir", "maps_to": "C1138226:favipiravir", "start": 0, "end": 11}], "has_relation": "N/A"}, "Observation": "77 %", "Outcome": "percentage of patients who turned viral negative after 14-day treatment", "Count": ""}, {"Intervention": {"term": "favipiravir", "has_chemical": [{"text": "favipiravir", "maps_to": "C1138226:favipiravir", "start": 0, "end": 11}], "has_relation": "N/A"}, "Observation": "100 %", "Outcome": "percentage of patients who turned viral negative after 14-day treatment", "Count": ""}, {"Intervention": {"term": "favipiravir", "has_chemical": [{"text": "favipiravir", "maps_to": "C1138226:favipiravir", "start": 0, "end": 11}], "has_relation": "N/A"}, "Observation": "100 %", "Outcome": "medians of time from randomization to clinical", "Count": ""}, {"Intervention": {"term": "control", "has_relation": "N/A"}, "Observation": "100 %", "Outcome": "percentage of patients who turned viral negative after 14-day treatment", "Count": ""}, {"Intervention": {"term": "control", "has_relation": "N/A"}, "Observation": "100 %", "Outcome": "medians of time from randomization to clinical", "Count": ""}]}, {"Section": "RESULTS", "Text": "One reason for the lack of virological effect and clinical benefits may be due to insufficient concentrations of these drugs relative to their antiviral activities .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "One of the limitations of this study is the time from symptom onset to randomization , especially in the baloxavir marboxil and control groups , which is higher than the favipiravir group .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "baloxavir marboxil", "negation": "affirmed", "UMLS": {}, "start": 105, "end": 123, "has_chemical": [{"text": "baloxavir marboxil", "maps_to": "C4688747:baloxavir marboxil", "start": 0, "end": 18}], "has_relation": "N/A"}, {"term": "control", "negation": "affirmed", "UMLS": {}, "start": 128, "end": 135, "has_relation": "N/A"}], "Outcome": [{"term": "time from symptom onset to randomization", "negation": "affirmed", "UMLS": {}, "start": 44, "end": 84}], "Observation": [{"term": "higher", "negation": "affirmed", "UMLS": {}, "start": 154, "end": 160}], "Count": []}, "Evidence Propositions": [{"Intervention": [{"term": "baloxavir marboxil", "has_chemical": [{"text": "baloxavir marboxil", "maps_to": "C4688747:baloxavir marboxil", "start": 0, "end": 18}], "has_relation": "N/A"}, {"term": "control", "has_relation": "N/A"}], "Observation": "higher", "Outcome": "time from symptom onset to randomization", "Count": ""}]}, {"Section": "CONCLUSIONS", "Text": "Our findings could not prove a benefit of addition of either baloxavir marboxil or favipiravir under the trial dosages to the existing standard treatment .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "addition of either baloxavir marboxil or favipiravir under the trial", "negation": "negated", "UMLS": {}, "start": 42, "end": 110, "has_chemical": [{"text": "baloxavir marboxil", "maps_to": "C4688747:baloxavir marboxil", "start": 19, "end": 37}, {"text": "favipiravir", "maps_to": "C1138226:favipiravir", "start": 41, "end": 52}], "has_relation": "or (C4688747<->C1138226)"}], "Outcome": [], "Observation": [{"term": "benefit", "negation": "negated", "UMLS": {}, "start": 31, "end": 38}], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Copyright \u00a9 2020 .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Published by Elsevier B.V .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}]}